Neoadjuvant therapy for high-risk bulky regional melanoma

Journal of Surgical Oncology

Volumn 104, Issue 4, 2011, Pages 386-390

  Tarhini, Ahmad A ^a,b   Pahuja, Shalu ^a,b   Kirkwood, John M ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

bulky; melanoma; neoadjuvant

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA2A INTERFERON; CD83 ANTIGEN; CISPLATIN; DACARBAZINE; E 1684; E 1690; E1690; EPITOPE; GLYCOPROTEIN P 15095; INTERLEUKIN 2; PEGINTERFERON ALPHA2B; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VACCINE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CONTINUOUS INFUSION; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAINTENANCE DRUG DOSE; MELANOMA; MORBIDITY; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SENTINEL LYMPH NODE; SIGNAL TRANSDUCTION; TH1 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; INTERFERON ALFA-2B; MELANOMA; NEOADJUVANT THERAPY; SKIN NEOPLASMS;

EID: 80052016114     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21882     Document Type: Review

References (43)

1. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
2. Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18: 3782-3793.
3. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193: 377-388. (Pubitemid 11114057)
4. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634. (Pubitemid 32786275)
5. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17. (Pubitemid 26019991)
6. Kirkwood JM, Ibrahim JG, Sondak VK, et al.: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-2458. (Pubitemid 30415832)
7. Kirkwood JM, Ibrahim JG, Sosman JA, et al.: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-2380. (Pubitemid 32391207)
8. Wheatley K, Eggermont A, Kirkwood JM:, Interferon-alfa as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. In: ASCO Annual Meeting; 2007 June; Chicago; 2007.
9. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 2010; 107: 493-501.
10. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-1310. (Pubitemid 26102328)
11. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007; 25: 869-875. (Pubitemid 350002888)
12. Hakansson A, Gustafsson B, Krysander L, et al. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996; 74: 670-676. (Pubitemid 26300755)
13. Mihm MC Jr, Clemente CG, Cascinelli N:, Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 43-47. (Pubitemid 26041007)
14. Moschos SJ, Edington HD, Land SR, et al.: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24: 3164-3171. (Pubitemid 46638955)
15. Nishimura T, Nakui M, Sato M, et al.: The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46 (Suppl) S52-S61.
16. Tatsumi T, Kierstead LS, Ranieri E, et al.: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196: 619-628. (Pubitemid 35024440)
17. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677. (Pubitemid 38435557)
18. Eggermont A, Suciu S, Ruka W:, EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J Clin Oncol 2008; 26: (May 20 suppl; abstr 9004). In: 2008 ASCO Annual Meeting 2008;Chicago; 2008.
19. Ives NJ:, Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25: 5426-5434. (Pubitemid 350232219)
20. Wheatley K, Ives N, Eggermont A, et al.: Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol 2007; 25: 8526.
21. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treatment Rev 2003; 29: 241-252. (Pubitemid 37069655)
22. Grossman HB, Natale RB, Tangen CM, et al.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866. (Pubitemid 37025405)
23. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493. (Pubitemid 27289876)
24. Group MRCOCW:, Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-1733.
25. Buzaid AC, Colome M, Bedikian A, et al.: Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998; 8: 549-556. (Pubitemid 29046506)
26. Gibbs P, Anderson C, Pearlman N, et al.: A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer 2002; 94: 470-476. (Pubitemid 34081378)
27. Keilholz U, Punt CJ, Gore M, et al.:, Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747-6755. (Pubitemid 46190270)
28. Atkins MB, Hsu J, Lee S, et al.: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26: 5748-5754.
29. Su YB, Sohn S, Krown SE, et al.: Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J Clin Oncol 2004; 22: 610-616. (Pubitemid 41095063)
30. Kirkwood JM, Ernstoff MS, Davis CA, et al. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103: 32-36. (Pubitemid 15068495)
31. Pestka S:, The interferon receptors. Semin Oncol 1997; 24: S9-18-S9-40.
32. Lesinski GB, Anghelina M, Zimmerer J, et al.: The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003; 112: 170-180. (Pubitemid 38056353)
33. Kirkwood JM, Farkas DL, Chakraborty A, et al.: Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 1999; 5: 11-20. (Pubitemid 29282093)
34. Wang T, Niu G, Kortylewski M, et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54. (Pubitemid 38524698)
35. Kirkwood JM, Moschos S, Wang W:, Strategies for the development of more effective adjuvant therapy of melanoma: Current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006; 12: 2331s-2336s.
36. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
37. Flaherty KT, Puzanov I, Kim KB, et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363: 809-819.
38. Flaherty K, Puzanov I, Sosman J:, Phase I study of PL X4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27: 2009; 15s (suppl; abstr 9000).
39. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346. (Pubitemid 46630793)
40. Wyman K, Atkins MB, Prieto V, et al.: Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer 2006; 106: 2005-2011. (Pubitemid 43673217)
41. Eton O, Billings L, Kim K:, Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma. Journal of Clinical Oncology 2004; 22: No 14S (July 15 Supplement), abstr 7528.
42. Kluger HM, Dudek A, McCann C:, A phase II trial of dasatinib in advanced melanoma. J Clin Oncol 27: 2009; (suppl; abstr 9010).
43. Carvajal RD, Chapman PB, JD W:, A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 27: 2009; 15S (suppl; abstr 9001).